Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nektar Branches Out In Pain, Hails Next Generation Of Analgesics

Executive Summary

At R&D event, company signals shift of Phase III for lead pain drug NKTR-181 to mid-2014 from earlier in the year. Nektar also featured crop of new drugs targeted at different molecular pathways, including NKTR-192, a partial agonist for acute pain, and a new kind of sodium channel blocker called NKTR-171 for neuropathy.

You may also be interested in...



Nektar Edges Into Immunotherapy With Better Interleukin-2 Drug

Building on foundation of IL-2 inhibition in immunotherapy, Nektar introduces an improved stimulatory cytokine available on outpatient basis, NKTR-214, for a number of tumor types.

Nektar Builds Case For Irinotecan-Inspired NKTR-102 In Cancer

Company’s R&D day stresses areas of unmet need for NKTR-102 in metastatic breast cancer. Company also highlights data from a Phase II study showing the drug’s promise in high-grade brain cancer.

Nektar Builds Case For Irinotecan-Inspired NKTR-102 In Cancer

Company’s R&D day stresses areas of unmet need for NKTR-102 in metastatic breast cancer. Company also highlights data from a Phase II study showing the drug’s promise in high-grade brain cancer.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS055672

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel